유럽의 생물학적 제제 CDMO 시장 : 세포 유형별, 분자 유형별, 국가별 - 분석 및 예측(2023-2032년)

Introduction to Europe Biologics CDMO Market

The Europe biologics CDMO market is projected to reach $21.61 billion by 2032 from $6.48 billion in 2023, growing at a CAGR of 14.32% during the forecast period 2023-2032. The market's trajectory indicates a transformative impact on pharmaceutical care. Companies that skillfully navigate regulatory complexities and adopt technological innovations are well-positioned for significant success.

Market Introduction

The Europe Biologics CDMO market is experiencing robust growth, driven by increasing demand for biologic therapies, such as monoclonal antibodies, vaccines, and cell and gene therapies. The rise in chronic diseases, advancements in biology, and the growing trend of outsourcing drug development and manufacturing processes are key factors propelling the market. European CDMOs are investing in state-of-the-art facilities and cutting-edge technologies to enhance production capabilities and meet stringent regulatory standards. Strategic collaborations and partnerships are also on the rise, enabling CDMOs to offer comprehensive services from early development to commercial manufacturing. With strong government support and a well-established biopharmaceutical sector, the Europe Biologics CDMO market is poised for sustained expansion and innovation.

Market Segmentation:

Segmentation 1: by Cell Type

• Mammalian
• Microbial and Others

Segmentation 2: by Molecule Type

• Monoclonal Antibodies
• Recombinant Proteins
• Vaccines
• Hormones
• Others

Segmentation 3: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Workflow/Innovation Strategy: The Europe biologics CDMO market (by molecule type) has been segmented into different types of molecules used in developing biologics. Moreover, the study provides the reader with a detailed understanding of the different cell types and indications as well.

Growth/Marketing Strategy: The market growth and marketing strategy of biologics CDMO market revolves around a combination of technical excellence, strategic collaborations, and market positioning. CDMOs leverage their specialized expertise in bioprocessing and manufacturing to offer comprehensive solutions to biopharmaceutical companies.

Competitive Strategy: Key players in the Europe biologics CDMO market have been analyzed and profiled in the study, including CDMOs involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the biologics CDMO market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

• Boehringer Ingelheim Group
• Lonza Group
• NOVARTIS AG

Table of Contents

Executive Summary

1 Scope and Definition

• 1.1 Market Definition
• 1.2 Key Questions Answered in the Report
• 1.3 Analyst and Forecast Note

2 Markets: Industry Outlook

• 2.1 Trends: Current and Future Impact Assessment
  • 2.1.1 Trend 1 - Increasing Biomanufacturing Capacity
  • 2.1.2 Trend 2 - Single-use Bioprocessing Equipment
  • 2.1.3 Trend 3 - Trend Toward Personalized Medicine
• 2.2 Market Footprint
• 2.3 Supply Chain Overview
• 2.4 Patent Analysis
• 2.5 Regulatory Landscape
• 2.6 Factors Considered While Outsourcing To CDMO
• 2.7 Market Dynamics Overview
• 2.8 Market Drivers
• 2.9 Market Restraints
• 2.10 Market Opportunities

3 Global Biologics CDMO Market, by Region, 2022-2032

• 3.1 Regional Summary
• 3.2 Drivers and Restraints
• 3.3 Europe
  • 3.3.1 Europe Biologics CDMO Market, by Cell Type
  • 3.3.2 Europe Biologics CDMO Market, by Molecule Type
  • 3.3.3 Europe (by Country)
    • 3.3.3.1 Germany
      • 3.3.3.1.1 Germany Biologics CDMO Market, by Cell Type
      • 3.3.3.1.2 Germany Biologics CDMO Market, by Molecule Type
    • 3.3.3.2 U.K.
      • 3.3.3.2.1 U.K. Biologics CDMO Market, by Cell Type
      • 3.3.3.2.2 U.K. Biologics CDMO Market, by Molecule Type
    • 3.4.3.3 France
      • 3.4.3.3.1 France Biologics CDMO Market, by Cell Type
      • 3.4.3.3.2 France Biologics CDMO Market, by Molecule Type
    • 3.4.3.4 Italy
      • 3.4.3.4.1 Italy Biologics CDMO Market, by Cell Type
      • 3.4.3.4.2 Italy Biologics CDMO Market, by Molecule Type
    • 3.4.3.5 Spain
      • 3.4.3.5.1 Spain Biologics CDMO Market, by Cell Type
      • 3.4.3.5.2 Spain Biologics CDMO Market, by Molecule Type
    • 3.4.3.6 Rest-of-Europe
      • 3.4.3.6.1 Rest-of-Europe Biologics CDMO Market, by Cell Type
      • 3.4.3.6.2 Rest-of-Europe Biologics CDMO Market, by Molecule Type

4 Markets - Competitive Benchmarking & Company Profiles

• 4.1 Competitive Landscape
• 4.2 Boehringer Ingelheim International GmbH
• 4.3 Lonza
• 4.4 Novartis AG

Research Methodology